InMed Pharmaceuticals Inc.
INM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1,120 | $1,777 | $1,262 | $1,112 |
| % Growth | -37% | 40.9% | 13.5% | – |
| Cost of Goods Sold | $717 | $992 | $1,086 | $651 |
| Gross Profit | $403 | $785 | $176 | $461 |
| % Margin | 36% | 44.2% | 13.9% | 41.5% |
| R&D Expenses | $582 | $154 | $910 | $1,060 |
| G&A Expenses | $1,532 | $3,069 | $1,329 | $1,554 |
| SG&A Expenses | $1,532 | $3,069 | $1,329 | $1,554 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $53 | $0 | $52 | $53 |
| Operating Expenses | $2,167 | $3,223 | $2,291 | $2,667 |
| Operating Income | -$1,764 | -$2,437 | -$2,115 | -$2,206 |
| % Margin | -157.5% | -137.1% | -167.7% | -198.5% |
| Other Income/Exp. Net | $37 | $1 | -$6 | -$369 |
| Pre-Tax Income | -$1,727 | -$2,436 | -$2,121 | -$2,575 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1,727 | -$2,436 | -$2,121 | -$2,575 |
| % Margin | -154.2% | -137.1% | -168.1% | -231.6% |
| EPS | -436.69 | -1.22 | -2.77 | -5.24 |
| % Growth | -35,694.3% | 56% | 47.1% | – |
| EPS Diluted | -436.69 | -1.22 | -2.77 | -5.24 |
| Weighted Avg Shares Out | 4 | 2,002 | 1,096 | 707 |
| Weighted Avg Shares Out Dil | 4 | 2,002 | 1,096 | 707 |
| Supplemental Information | – | – | – | – |
| Interest Income | $94 | $52 | $17 | $31 |
| Interest Expense | $0 | $20 | $0 | $352 |
| Depreciation & Amortization | $157 | $72 | $130 | $129 |
| EBITDA | -$1,570 | -$2,437 | -$1,991 | -$2,094 |
| % Margin | -140.2% | -137.1% | -157.8% | -188.4% |